Chapter 2 · Financial Health
Still losing
money — but
almost not.
The loss is shrinking fast as revenue scales past the cost of the launch.
↓ scroll to read
✦ The bottom line
Madrigal's 2025 operating loss was $300M — large, but small next to $958M of revenue, and narrowing every quarter (the most recent was a ~$93M loss). Unlike a pre-revenue biotech, Madrigal is in the final stretch: scale the launch a bit further and the drug's high margins should tip it into profit.
↓ the brief below
✦ Teach me
Operating leverage in drugs
Once a drug is approved, making each additional dose costs very little — pharma gross margins are famously high. The big costs are fixed: the salesforce, marketing, and ongoing R&D.
So as revenue climbs, it eventually overtakes those fixed costs and profit appears suddenly — 'operating leverage.' Madrigal is right at that tipping point: revenue is racing up while the cost base grows slowly.
Wall Street calls this
Operating leverage / path to profit
It's the difference between a biotech that *might* someday make money and one that almost certainly will *soon*. Madrigal is firmly in the second camp — a notably less risky financial profile than most spicy names.